“…In rodent studies, sEHIs have shown promising results for controlling various inflammatory diseases, such as hypertension, atherosclerosis, diabetes, COPD, liver regeneration, fibrosis, sepsis, asthma, subarachnoid hemorrhage, arthritis, and neuropathic pain ( 27 , 41 , 57 , 96 – 104 ). Thus, sEH is a critical cause of and biomarker for inflammation in many systems ( 40 , 50 , 53 , 84 , 99 , 105 – 107 ). The human sEHI EC5026 is in clinical development as an analgesic for neuropathic pain as a nonaddictive opioid alternative ( 42 ).…”